ArticleEuropean journal of pain (London, England)2025
Breast Cancer Cell Lines AT-3 and E0771 Decrease Mechanical and Cold Sensitivity, Along With Oestrous Cycle and Inflammatory Marker Alterations, in Wild-Type C57BL/6J Female Mice.
Article in European journal of pain (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Breast Cancer Cell Lines AT-3 and E0771 Decrease Mechanical and Cold Sensitivity, Along With Oestrous Cycle and Inflammatory Marker Alterations, in Wild-Type C57BL/6J Female Mice.European journal of pain (London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundBreast cancer represents the most common cancer diagnosis and the leading cause of cancer-related death in women. Cancer is also associated with pain and changes in both tactile and temperature sensitivity that impair quality of life. While previous studies have investigated the effects of various chemotherapies in murine models of these symptoms, few have previously assessed the effects of cancer alone on these symptoms.
methodsWe evaluated the efficacy of murine AT-3 and E0771 breast cancer cell lines on the rate of tumour growth using the Von Frey test (mechanical sensitivity/allodynia) and the acetone test (cold sensitivity/allodynia) in female C57BL/6J wild-type mice. Evaluations for changes in oestrous cycle and mRNA expression in both tumour and whole brain tissue were then performed.
resultsWhile both cancer cell lines induced significant tumour growth, this growth was significantly greater in the AT-3 cell line than in the E0771 cell line. The AT-3 cell line significantly decreased mechanical and cold sensitivity (allodynia) and significantly altered the oestrous cycle to increase the time spent in a low oestrogen phase (oestrus). In comparison, the E0771 cell line significantly decreased mechanical and cold sensitivity (allodynia) without oestrous cycle alterations. When comparing gene expression in tumour tissue between the two cell lines, the E0771 cell line significantly increased expression of fatty acid amide hydrolase and calcitonin receptor-like.
conclusionsThese results demonstrate the significant impacts of breast cancer on mechanical and cold sensitivity and support the need for further investigations into possible interactions between cancer and chemotherapy in these modalities. SIGNIFICANCE STATEMENT: Cancer-associated pain and altered sensations significantly decrease patient quality of life. In our murine model, we have shown that breast cancer cell lines (AT-3 and E0771) alter mechanical and cold sensitivity. These changes coincided with oestrous cycle changes (AT-3) and mRNA expression changes (E0771). A better understanding of our findings will elucidate different mechanisms of action while identifying preventative strategies and potential interactions with chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.